medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-29-8-12medalphabet-2254Research ArticleСтатьиЭмпаглифлозин у пациента с сердечной недостаточностью и сахарным диабетом второго типа: новые возможности медикаментозной терапииEmpagliflozin in patient with heart failure and type 2 diabetes mellitus: new possibilities for drug therapyhttps://orcid.org/0000-0001-7058-2008СедыхД. Ю.SedykhD. Yu.

Седых Дарья Юрьевна, к.м.н., н.с. лаборатории патологии кровообращения отдела клинической кардиологии 

г. Кемерово

Barbarash Olga L., DM Sci, professor, corresponding member of RAS, director, head of Dept of Cardiology and Cardiovascular Surgery

Kemerovo

md-sedih@mail.ruhttps://orcid.org/0000-0003-3729-616XКашталапВ. В.KashtalapV. V.

Кашталап Василий Васильевич, д.м.н., доцент, зав. отделом клинической кардиологии, проф. кафедры кардиологии и сердечно-сосудистой хирургии

г. Кемерово

Kashtalap Vasily V., DM Sci, associate professor, head of Dept of Clinical Cardiology

Kemerovo

v_kash@mail.ruhttps://orcid.org/0000-0002-4642-3610БарбарашО. Л.BarbarashO. L.

Барбараш Ольга Леонидовна, д.м.н., проф., член-корр. РАН, директор, зав. кафедрой кардиологии и сердечно-сосудистой хирургии

г. Кемерово

Barbarash Olga L., DM Sci, professor, corresponding member of RAS, director, head of Dept of Cardiology and Cardiovascular Surgery 

Kemerovo

olb61@mail.ruФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»РоссияResearch Institute for Complex Problems of Cardiovascular DiseasesRussian Federation202119102021129Коморбидные состояния (2)812Copyright © Седых Д.Ю., Кашталап В.В., Барбараш О.Л., 20212021Седых Д.Ю., Кашталап В.В., Барбараш О.Л.Sedykh D.Y., Kashtalap V.V., Barbarash O.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2254

В статье продемонстрирован практический опыт эффективного применения представителя ингибиторов натрий-глюкозного котранспортера 2 эмплаглифлозина в составе оптимальной медикаментозной терапии у пациентов при декомпенсированной хронической сердечной недостаточности с систолической дисфункцией ишемического генеза и сахарном диабете второго типа. На основании данных доказательных исследований обозначено место данной группы лекарственных препаратов в улучшении качества жизни и прогноза у пациентов с тяжелой коморбидностью.

The article demonstrates the practical experience of the effective use of inhibitor of sodium-glucose co-transporter 2 emplagliflozin as a part of optimal drug therapy in patients with decompensation of chronic heart failure with systolic dysfunction of ischemic genesis and type 2 diabetes mellitus. The place of this group of drugs in improving the quality of life and prognosis in patients with severe comorbidity has been indicated according to the data of evidence-based studies.

сердечная недостаточностьсахарный диабетпрогнозингибиторы натрий-глюкозного котранспортера 2эмпаглифлозинheart failurediabetes mellitusprognosissodium glucose co-transporter 2 (SGLT2) inhibitorsempagliflozinСтатья публикуется при поддержке ООО «Берингер Ингельхайм»This article is published with the support of Boehringer Ingelheim LLCReferencesБарбараш О. Л., Кашталап В. В. Место фармакоинвазивной тактики ведения пациентов с острым коронарным синдромом с подъемом сегмента ST в России. Кардиология. 2014; 9: 79–85. DOI: 10.18565/cardio.2014.9.79–85.Barbarash O.L., Kashtalap V.V. The Place of Pharmacoinvasive Management in Patients With ST-Elevation Acute Coronary Syndrome in Russia. Kardiologiia. 2014; 9: 79–85 (in Russian).Кашталап В.В., Завырылина И.Н., Барбараш О.Л. Креативная кардиология. 2015; 3: 5–15. DOI: 10.15275/kreatkard.2015.03.01.Kashtalap V. V., Zavyrylina I. N., Barbarash O. L. Endovascular revascularization for ST-elevation acute coronary syndrome in Russia: problems and prospects for the further development. Kreativnaya kardiologiya. 2015; 3: 5–15 (in Russian).Барбараш О.Л., Кашталап В.В., Быкова И.С. и др. Особенности клинического течения и стационарного этапа лечения пациентов с острым коронарным синдромом с подъемом сегмента ST в зависимости от пола (по данным Российского регистра острого коронарного синдрома «РЕКОРД-3»). Российский кардиологический журнал. 2017; 6 (146): 122–131. DOI: 10.15829/1560–4071–2017–6–122–131.Barbarash O.L., Kashtalap V.V., Bykova I.S., et al. Gender specifics of clinical course and in-patient stage of management in ST-elevation acute coronary syndrome patients (by the Russian Registry of Acute Coronary Syndrome RECORD-3. Russ J Cardiol. 2017; 6 (146): 122–131 (in Russian).Koudstaal S., Pujades-Rodriguez M., Denaxas S., et al. Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people. Eur J Heart Fail. 2017; 19 (9): 1119–1127. DOI: 10.1002/ejhf.709.Koudstaal S., Pujades-Rodriguez M., Denaxas S., et al. Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people. Eur J Heart Fail. 2017; 19 (9): 1119–1127. DOI: 10.1002/ejhf.709.Кобалава Ж. Д., Лазарев П. В., Виллевальде С. В. Ингибиторы SGLT2: обоснование и перспективы применения при сердечной недостаточности. Кардиология. 2018; 58 (2): 42–54. DOI: 10.18087/cardio.2018.2.10087.Kobalava Zh.D., Lazarev P.V., Villevalde S.V. SGLT2 Inhibitors: Rationale and Perspectives of Use in Heart Failure. Kardiologiia. 2018; 58 (2): 42–54 (in Russian).Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25 (11): 4083. DOI: 10.15829/1560–4071–2020–4083.2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020; 25 (11): 4083 (in Russian).McDonagh T.A., Metra M., Adamo M., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021: ehab368. DOI: 10.1093/eurheartj/ehab368.McDonagh T.A., Metra M., Adamo M., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021: ehab368. DOI: 10.1093/eurheartj/ehab368.Niessner A., Tamargo J., Koller L., et al. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J. 2018; 39 (24): 2274–2281. DOI: 10.1093/eurheartj/ehx625.Niessner A., Tamargo J., Koller L., et al. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J. 2018; 39 (24): 2274–2281. DOI: 10.1093/eurheartj/ehx625.Ehrenkranz J.R., Lewis N.G., Kahn C.R., et al. Phlorizin: a review. Diabetes Metab Res Rev. 2005; 2 1(1): 31–38.Ehrenkranz J.R., Lewis N.G., Kahn C.R., et al. Phlorizin: a review. Diabetes Metab Res Rev. 2005; 2 1(1): 31–38.Zelniker T.A., Wiviott S.D., Raz I., et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393 (10166): 31–39. DOI: 10.1016/S0140–6736(18)32590-X.Zelniker T.A., Wiviott S.D., Raz I., et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393 (10166): 31–39. DOI: 10.1016/S0140–6736(18)32590-X.Anker S.D., Butler J., Filippatos G., et al. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. Eur J Heart Fail. 2020; 22 (12): 2383–2392. DOI: 10.1002/ejhf.2064.Anker S.D., Butler J., Filippatos G., et al. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. Eur J Heart Fail. 2020; 22 (12): 2383–2392. DOI: 10.1002/ejhf.2064.Kaplinsky E. DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. Drugs Context. 2020; 9: 2019–11–3. DOI: 10.7573/dic.2019–11–3.Kaplinsky E. DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. Drugs Context. 2020; 9: 2019–11–3. DOI: 10.7573/dic.2019–11–3.Anker S.D., Butler J., Filippatos G., et al. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients with Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. Circulation. 2021; 143 (4): 337–349. DOI: 10.1161/circulationaha.120.051824.Anker S.D., Butler J., Filippatos G., et al. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients with Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. Circulation. 2021; 143 (4): 337–349. DOI: 10.1161/circulationaha.120.051824.Scheen A.J. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014; 53 (3): 213–225. DOI: 10.1007/s40262–013–0126-x.Scheen A.J. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014; 53 (3): 213–225. DOI: 10.1007/s40262–013–0126-x.Shyangdan D.S., Uthman O.A., Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016 Feb 24; 6 (2): e009417. DOI: 10.1136/bmjopen-2015–009417.Shyangdan D.S., Uthman O.A., Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016 Feb 24; 6 (2): e009417. DOI: 10.1136/bmjopen-2015–009417.Merovci A., Solis-Herrera C., Daniele G., et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014; 124 (2): 509–514. DOI: 10.1172/JCI70704.Merovci A., Solis-Herrera C., Daniele G., et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014; 124 (2): 509–514. DOI: 10.1172/JCI70704.Шестакова М.В., Сухарева О.Ю. Глифлозины: особенности сахароснижающего действия и негликемические эффекты нового класса препаратов. Клиническая фармакология и терапия. 2016; 25 (2): 65–71.Shestakova M. V., Sukhareva O. Yu. Gliflozins: glucose-lowering and nonglycemic effects of new class of antidiabetic medications. The Clin. Pharmacol. Ther. 2016; 25 (2): 65–71 (in Russian).Verbrugge F.H., Vangoitsenhoven R., Mullens W., et al. SGLT-2 inhibitors: potential novel strategy to prevent congestive heart failure in diabetes? Curr Cardiovasc Risk Rep. 2015; 9: 38.Verbrugge F.H., Vangoitsenhoven R., Mullens W., et al. SGLT-2 inhibitors: potential novel strategy to prevent congestive heart failure in diabetes? Curr Cardiovasc Risk Rep. 2015; 9: 38.Heerspink H.J., Perkins B.A., Fitchett D.H., et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016; 134: 752–772. DOI: 10.1161/CIRCULATIONAHA.116.021887.Heerspink H.J., Perkins B.A., Fitchett D.H., et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016; 134: 752–772. DOI: 10.1161/CIRCULATIONAHA.116.021887.Martens P., Mathieu C., Verbrugge F.H. Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond. Curr Treat Options Cardiovasc Med. 2017; 19 (3): 23. DOI: 10.1007/s11936–017–0522-x.Martens P., Mathieu C., Verbrugge F.H. Promise of SGLT2 Inhibitors in Heart Failure: Diabetes and Beyond. Curr Treat Options Cardiovasc Med. 2017; 19 (3): 23. DOI: 10.1007/s11936–017–0522-x.Chilton R., Tikkanen I., Cannon C. P., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015; 17: 1180–1193. DOI: 10.1111/dom.12572.Chilton R., Tikkanen I., Cannon C. P., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015; 17: 1180–1193. DOI: 10.1111/dom.12572.Di Franco A., Cantini G., Tani A., et al. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target. Int J Cardiol. 2017; 243: 86–90. DOI: 10.1016/j.ijcard.2017.05.032.Di Franco A., Cantini G., Tani A., et al. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target. Int J Cardiol. 2017; 243: 86–90. DOI: 10.1016/j.ijcard.2017.05.032.Terasaki M., Hiromura M., Mori Y., et al. Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice. PLOS ONE. 2015; 10: e0143396. DOI: 10.1371/journal.pone.0143396.Terasaki M., Hiromura M., Mori Y., et al. Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice. PLOS ONE. 2015; 10: e0143396. DOI: 10.1371/journal.pone.0143396.Baartscheer A., Schumacher C.A., Wüst R.C., et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017; 60: 568–573. DOI: 10.1007/s00125–016–4134-x.Baartscheer A., Schumacher C.A., Wüst R.C., et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017; 60: 568–573. DOI: 10.1007/s00125–016–4134-x.Bertero E., Prates Roma L., Ameri P., et al. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res. 2018; 114 (1): 12–18. DOI: 10.1093/cvr/cvx149.Bertero E., Prates Roma L., Ameri P., et al. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis. Cardiovasc Res. 2018; 114 (1): 12–18. DOI: 10.1093/cvr/cvx149.Neeland I.J., McGuire D.K., Chilton R., et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diabetes Vasc Dis Res. 2016; 13: 119–126. DOI: 10.1177/1479164115616901.Neeland I.J., McGuire D.K., Chilton R., et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diabetes Vasc Dis Res. 2016; 13: 119–126. DOI: 10.1177/1479164115616901.Packer M. Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus with That of Heart Failure. Circulation. 2017; 136 (16): 1548–1559. DOI: 10.1161/circulationaha.117.030418.Packer M. Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus with That of Heart Failure. Circulation. 2017; 136 (16): 1548–1559. DOI: 10.1161/circulationaha.117.030418.Leiter L.A., Cefalu W.T., de Bruin T.W., et al. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Obes Metab. 2016; 18 (8): 766–74. DOI: 10.1111/dom.12666.Leiter L.A., Cefalu W.T., de Bruin T.W., et al. Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease. Diabetes Obes Metab. 2016; 18 (8): 766–74. DOI: 10.1111/dom.12666.Neal B., Perkovic V., de Zeeuw D., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) – a randomized placebo-controlled trial. Am Heart J. 2013; 166 (2): 217–223. e11. DOI: 10.1016/j.ahj.2013.05.007.Neal B., Perkovic V., de Zeeuw D., et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) – a randomized placebo-controlled trial. Am Heart J. 2013; 166 (2): 217–223. e11. DOI: 10.1016/j.ahj.2013.05.007.Fitchett D., Zinman B., Wanner C., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME (R) trial. Eur Heart J. 2016; 37: 1526–1534. DOI: 10.1093/eurheartj/ehv728.Fitchett D., Zinman B., Wanner C., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME (R) trial. Eur Heart J. 2016; 37: 1526–1534. DOI: 10.1093/eurheartj/ehv728.Cannon C.P., Pratley R., Dagogo-Jack S., et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020; 383 (15): 1425–1435. DOI: 10.1056/NEJMoa2004967.Cannon C.P., Pratley R., Dagogo-Jack S., et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020; 383 (15): 1425–1435. DOI: 10.1056/NEJMoa2004967.Rhee J.J., Jardine M.J., Chertow G.M., et al. Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. Diabetes Obes Metab. 2020; 22 (1): 46–54. DOI: 10.1111/dom.13987.Rhee J.J., Jardine M.J., Chertow G.M., et al. Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. Diabetes Obes Metab. 2020; 22 (1): 46–54. DOI: 10.1111/dom.13987.Januzzi J.L. Jr, Butler J., Jarolim P., et al. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults with Type 2 Diabetes. J Am Coll Cardiol. 2017; 70 (6): 704–712. DOI: 10.1016/j.jacc.2017.06.016.Januzzi J.L. Jr, Butler J., Jarolim P., et al. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults with Type 2 Diabetes. J Am Coll Cardiol. 2017; 70 (6): 704–712. DOI: 10.1016/j.jacc.2017.06.016.Wanner C., Inzucchi S.E., Lachin J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375: 323–334. DOI: 10.1056/NEJMoa1515920.Wanner C., Inzucchi S.E., Lachin J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375: 323–334. DOI: 10.1056/NEJMoa1515920.Ahmed-Sarwar N., Nagel A. K., Leistman S., et al. SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management? Ann Pharmacother. 2017; 51 (9): 791–796. DOI: 10.1177/1060028017710481.Ahmed-Sarwar N., Nagel A. K., Leistman S., et al. SGLT-2 Inhibitors: Is There a Role in Type 1 Diabetes Mellitus Management? Ann Pharmacother. 2017; 51 (9): 791–796. DOI: 10.1177/1060028017710481.Cosentino F., Grant P.J., Aboyans V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal. 2020; 41: 255–323. DOI: 10.1093/eurheartj/ehz486.Cosentino F., Grant P.J., Aboyans V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal. 2020; 41: 255–323. DOI: 10.1093/eurheartj/ehz486.Барбараш О. Л., Гарганеева А. А., Гоголашвили Н. Г. и др. Резолюция совещания экспертов Сибирского федерального округа «Эмпаглифлозин и сердечная недостаточность» по результатам исследования EMPEROR-Reduced. Комплексные проблемы сердечно-сосудистых заболеваний. 2021; 10 (1): 103–108. DOI: 10.17802/2306–1278–2021–10–1–103–108.Barbarash O.L., Garganeeva A.A., Gogolashvili N.G., et al. The resolution on empagliflozin and heart failure has been adopted by the experts of the Siberian Federal District based on the results of the EMPEROR-Reduced study. Complex Issues of Cardiovascular Diseases. 2021; 10 (1): 103–108 (in Russian).

The authors declare that there are no conflicts of interest present.